Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation – a double‐blind, randomized, placebo‐controlled, study

Abstract

Given the limited increase in efficacy over placebo and the incidence of ischaemic colitis observed, our data suggest that the benefit/risk ratio of renzapride is not sufficient to warrant further study in IBS-C.